Friday, 18 Jan 2019

You are here

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.

Data claims were derived from a large US commercial health plan, and identified PsA patients initiating DMARD therapy and changes in the DMARD regimen over the next 12‐month period.

Among the 9,222 PsA patients who initiated DMARD therapy, 57% started with a conventional synthetic DMARDs [csDMARDs] and 43% began with a biologic DMARD [bDMARD].

Those starting on bDMARDs tended to be younger (48 yrs vs 52 yrs) and had fewer comorbidities.

Methotrexate was the most frequently used csDMARD (80.6%) and etanercept (49.1%) was the most commonly prescribed bDMARD, followed by adalimumab (34.4%).

In the first 12‐months 20.1% of bDMARD initiators and 31.1% of csDMARD initiators had a change in their DMARD regimen.

Very few patients (5.3%) totally discontinued therapy, but the rates of discontinuation decreased over time (P < 0.001).

These data suggest that  the majority of PsA patients initiating DMARD therapy will remain on DMARD therapy for many years.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diet and Weight Loss Improves Psoriatic Arthritis

Short-term intervention with the very low energy diet (VLED) in psoriatic arthritis (PsA) with obesity (body mass index BMI ≥ 33 kg/m2) showed that weight loss was associated with significant positive benefits on weight and disease activity in joints, entheses and skin. 

H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis

Lilly has issued an advanced press release on its SPIRIT-H2H trial, wherein ixekizumab (Taltz) was shown to be more effective than than adalimumab (Humira) in a 24 week psoriatic arthritis study.

SPIRIT-H2H study was designed as a large head-to-head (H2H) superiority study to assess the efficacy and safety of ixekizumab versus adalimumab active psoriatic arthritis (PsA) patients who are biologic naive.

Psoriatic Arthritis Does Not Add to Pregnancy Problems

When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.

This study is relevant as the average onset age of PsA ranges between the 4th-6th decades of life and therefore includes a period of child-bearing potential.

IL-23 Outduels IL-17 Inhibition in Psoriasis

Johnson & Johnson has announced the preliminary results of its phase 3 ECLIPSE study; a head-to-head trial wherein guselkumab (Tremfya; an IL-23 inhibitor) was compared to secukinumab (Cosentyx; an IL-17 inhibitor) in adults with moderate to severe plaque psoriasis.

New ACR/NPF Guidelines for Management of Psoriatic Arthritis

The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) have released a joint treatment guideline for psoriatic arthritis (PsA) that provides evidence-based pharmacologic and non-pharmacologic recommendations and includes recommendations on other management issues including vaccinations, psoriatic spondylitis, enthesitis, and treatment in the presence of inflammatory bowel disease, diabetes, or serious infections.